Skip Navigation


NDT Plus Advance Access originally published online on March 3, 2008
NDT Plus 2008 1(3):151-153; doi:10.1093/ndtplus/sfn016
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1/3/151    most recent
sfn016v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wiebe, C.
Right arrow Articles by Bohm, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Spinal cord compression from a brown tumour despite maximal medical therapy with cinacalcet and sevelamer

Chris Wiebe, Julie Ho, Barry Cohen and Clara Bohm

Department of Nephrology, University of Manitoba, Manitoba, Canada

Correspondence: Chris Wiebe, Department of Nephrology, University of Manitoba, Manitoba, Canada. E-mail: umwieb18@cc.umanitoba.ca

Key Words: brown tumour • cinacalcet • secondary hyperparathyroidism • spinal cord compression

Received for publication December 29, 2007. Accepted for publication January 28, 2008.

The first 10% of the full text of this article appears below.


   Background
 
Secondary hyperparathyroidism is a common complication of end-stage renal disease (ESRD), which occurs as a result of hyperphosphataemia, hypovitaminosis D and hypocalcaemia. Chronic hyperparathyroidism can result in osteitis fibrosis cystica, also known as brown tumours. Spinal cord compression from a brown tumour is a rare emergency and of the eight reported cases in the literature, this represents the first case while undergoing treatment with sevelamer and cinacalcet. Although cinacalcet may have a role in the metabolic control of hyperparathyroidism, caution needs to be taken in delay or avoidance of parathyroidectomy in severe cases, as it may cause delays in necessary therapy.


   Case report
 
A 33-year-old obese aboriginal . . . [Full Text of this Article]


   Discussion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?